|
市場調查報告書
產業分析：變化中的全球精神疾病治療藥經銷權趨勢
Industry Analysis--Changing Dynamics in Worldwide Psychiatric Franchises
|
本報告已在2011年12月21日停止出版。
在精神疾病治療的領域中，患者為了更有效治療，正嘗試著各種併用藥物的治療方法。針對精神疾病的治療雖然已經達成抑制病情加劇和造成永久性傷害的長期目標，但是針對個別患者的治療發展，仍留有待解決的課題。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對全球精神疾病治療藥經銷權趨勢進行調查分析，並系統整理調查結果後出版報告書 "Industry Analysis--Changing Dynamics in Worldwide Psychiatric Franchises" 。
本報告書內容包括：精神疾病的概要及全球治療藥的趨勢、大型製藥企業、中規模製藥企業的經銷權趨勢、未來發展前景等。共計18頁的內容綱要摘記如下：
實施概要
概要
精神疾病
全球精神疾病治療藥市場：領導品牌
主要精神疾病治療藥經銷權
- 大型製藥企業經銷權
- AstraZeneca
- GlaxoSmithKline
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- Sanofi-Aventis
- Wyeth
- 中型製藥企業經銷權
- 非專利藥品製藥企業的經銷權
最近精神疾病市場中的合作
未來發展前景
圖
- 精神疾病患者趨勢：2006年
- 針對精神疾病的暢銷藥：2005年
- 主要全球精神疾病治療藥經銷權：大型・中型製藥企業：2005年
- 全球非專利藥品製藥企業的經銷權：2005年
- 抗憂鬱劑相關基因治療藥
表
Abstract
Introduction
The treatment of psychiatric diseases is hardly straightforward; patients
often try many different drug regimens and combinations in order to identify
an optimal course of therapy. Although the long-term goal in treating
psychiatric diseases is to halt disease progression and to prevent the onset
of permanent damage, a more attainable step will be to individualize treatment
for patients using available drugs.
Get the Answers You Need to Shape Your Strategy
Psychiatric franchises are transforming as industry players concede potential
opportunities to others, capitalize on available opportunities, or challenge
others for coveted opportunities. What are the major psychiatric
franchises? What characteristics of the psychiatric industry make for a
dynamic market? Few innovative psychiatric drugs are in development;
however, psychiatric disease markets are substantial. Yet, big pharma' s
single-minded focus on developing the next blockbuster drug concedes a large
portion of pharmaceutical drug markets to midsize pharma companies. Which
midsize companies have the largest psychiatric franchises, and how are they fi
lling the market space conceded by big pharma? Identifying the genetic
variations associated with psychiatric diseases will be essential in the
development of drugs that provide personalized treatment options for patients.
What pharmacogenomics-based agents are currently in development?
Scope
- Psychiatric diseases: overview and prevalence of the major
psychiatric diseases in the seven major pharmaceutical markets (United States,
Europe France, Germany, Italy, Spain, and the United Kingdom, and
Japan).
- Worldwide psychiatric markets: a description of the psychiatric
pharmaceutical industry and the top-selling psychiatric drug brands of 2005.
- Major psychiatric franchises: dominant big pharma, midsize pharma,
and generics franchises.
- Psychiatric deals: a description of the recent license and
collaboration deals in the psychiatric industry.
- Outlook: the impact of industry dynamics on pharmaceutical
companies.
Mentioned in This Report-Companies
- Abbott Laboratories
- Affymetrix
- Albany Molecular Research
- Alza
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Carlsson Research
- Clinical Data
- Dr. Reddy' s Laboratories
- Eisai
- Eli Lilly
- Forest
- GlaxoSmithKline
- Ivax
- Johnson & Johnson
- Lundbeck
- Memory Pharmaceuticals
- Merck KGaA
- Mylan
- NeuroSearch
- Novartis
- Organon
- Otsuka
- Perlegen Sciences
- Pfi zer
- PGxHealth
- Reckitt Benckiser
- Sandoz
- Sanofi -Aventis
- Servier
- Shire Pharmaceuticals
- Solvay
- Targacept
- Teva Pharmaceuticals
- UCB
- Vanda Pharmaceuticals
- Verispan
- Vintage Pharmaceuticals
- Watson Pharmaceuticals
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Psychiatric Diseases
- Worldwide Psychiatric Markets-Top Brands
- Major Psychiatric Franchises
- Big Pharma Franchises
- AstraZeneca
- GlaxoSmithKline
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- Sanofi-Aventis
- Wyeth
- Midsize Pharma Franchises
- Generics Franchises
- Recent Psychiatric Deals
- Outlook
Figures
- 1. Total Prevalent Cases of Select Patient Populations, 2006
- 2. Blockbuster Psychiatric Drugs, 2005
- 3. Major Worldwide Psychiatric Franchises-Big and Midsize Pharma, 2005
- 4. Worldwide Generics Psychiatric Franchises, 2005
- 5. Genotype-Based Drug Doses for Antidepressants
Tables
- 1. Select Psychiatric Deals, 2005-2006
|
